Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antiba… Read more
Insmed Inc (INSM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.232x
Based on the latest financial reports, Insmed Inc (INSM) has a cash flow conversion efficiency ratio of -0.232x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-219.76 Million) by net assets ($945.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Insmed Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Insmed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Insmed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Insmed Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fair Isaac Corporation
NYSE:FICO
|
-0.096x |
|
TRIP.COM GROUP DL-00125
F:CLVB
|
N/A |
|
AGNC Investment Corp
NASDAQ:AGNCL
|
0.010x |
|
CaixaBank S.A
PINK:CIXPF
|
0.010x |
|
Edison International
NYSE:EIX
|
0.110x |
|
Amrize Ltd
NYSE:AMRZ
|
0.066x |
|
Willis Towers Watson PLC
NASDAQ:WTW
|
0.096x |
|
KBC Groep NV
BR:KBC
|
-0.345x |
Annual Cash Flow Conversion Efficiency for Insmed Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Insmed Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $285.38 Million | $-683.88 Million | -2.396x | -248.33% |
| 2023-12-31 | $-331.92 Million | $-536.25 Million | 1.616x | +135.48% |
| 2022-12-31 | $87.95 Million | $-400.44 Million | -4.553x | -414.41% |
| 2021-12-31 | $410.47 Million | $-363.30 Million | -0.885x | -11.32% |
| 2020-12-31 | $275.88 Million | $-219.35 Million | -0.795x | +17.00% |
| 2019-12-31 | $261.67 Million | $-250.65 Million | -0.958x | +22.67% |
| 2018-12-31 | $208.27 Million | $-257.98 Million | -1.239x | -180.20% |
| 2017-12-31 | $361.06 Million | $-159.62 Million | -0.442x | +53.45% |
| 2016-12-31 | $154.48 Million | $-146.71 Million | -0.950x | -193.95% |
| 2015-12-31 | $311.70 Million | $-100.70 Million | -0.323x | +6.60% |
| 2014-12-31 | $186.24 Million | $-64.42 Million | -0.346x | -6.23% |
| 2013-12-31 | $143.32 Million | $-46.66 Million | -0.326x | -26.91% |
| 2012-12-31 | $120.88 Million | $-31.01 Million | -0.257x | -14.04% |
| 2011-12-31 | $134.27 Million | $-30.20 Million | -0.225x | -461.80% |
| 2010-12-31 | $192.84 Million | $-7.72 Million | -0.040x | +54.94% |
| 2009-12-31 | $123.91 Million | $-11.01 Million | -0.089x | -102.09% |
| 2008-12-31 | $-2.82 Million | $-11.99 Million | 4.248x | +293.23% |
| 2007-12-31 | $11.49 Million | $-25.25 Million | -2.198x | +27.70% |
| 2006-12-31 | $13.88 Million | $-42.20 Million | -3.041x | -15.31% |
| 2005-12-31 | $10.53 Million | $-27.77 Million | -2.637x | +23.38% |
| 2004-12-31 | $7.24 Million | $-24.90 Million | -3.442x | -738.53% |
| 2003-12-31 | $26.22 Million | $-10.76 Million | -0.410x | +60.04% |
| 2002-12-31 | $23.45 Million | $-24.08 Million | -1.027x | -92.93% |
| 2001-12-31 | $59.70 Million | $-31.78 Million | -0.532x | -140.59% |
| 2000-12-31 | $96.78 Million | $-21.42 Million | -0.221x | +86.35% |
| 1999-12-31 | $4.46 Million | $-7.23 Million | -1.621x | -- |